Neurizon Investor Briefings Invitation
Released
Released
Announcement PDF
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
Neurizon Investor Briefings Invitation
Highlights:
• Neurizon is launching a national investor engagement series, commencing with in-person investor
briefings in Sydney on Thursday, 30 April, 2026 and Perth on Monday, 4 May, 2026
• Interim Executive Chairman, Sergio Duchini, will provide an update on recent progress and upcoming
milestones, followed by an interactive Q&A and networking session
• Additional dates and capital city locations to be announced shortly
16 April 2026 – Melbourne Australia: Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF)
(“Neurizon” or “the Company”), a clinical-stage biotechnology company dedicated to advancing innovative
treatments for neurodegenerative diseases, is pleased to invite shareholders and prospective investors to attend in-
person investor briefings being held in Sydney during April and Perth during May.
During the briefing, Interim Executive Chairman, Sergio Duchini will present an update on recent corporate, clinical
and operational progress, as well as upcoming value-defining milestones for NUZ-001.
The formal presentation will be followed by an interactive Q&A session and the opportunity to network with members
of the management team over drinks and canapés.
Interim Executive Chairman, Mr Sergio Duchini commented: “We are pleased to invite investors to attend our
upcoming in-person briefing sessions, which will be the first in a series of events to be held in major capital cities
across Australia. We are entering a defining period for Neurizon, with a number of important clinical and corporate
milestones ahead. These in-person events provide an opportunity to engage directly with our shareholder community
and reinforce the strategic foundations underpinning our growth.
We look forward to announcing additional locations shortly and to meeting with as many members of the investment
community as possible over the course of the year.”
Event details
Sydney Perth
Date Thursday, 30 April, 2026 Date Monday, 4 May, 2026
Time 5:00 – 7:00pm AEST Time 5:00 – 7:00pm AWST
Location Morgans
Aurora Place, Level 21/88 Phillip St,
Sydney
Location Morgans
Level 4, 50 Colin St
West Perth
RSVP By Thursday, 23 April, 2026
irpr@irdepartment.com.au – please note
in your email that you would like to attend
the Neurizon Sydney investor briefing
event.
RSVP By Friday, 24 April, 2026
irpr@irdepartment.com.au – please note
in your email that you would like to
attend the Neurizon Perth investor
briefing event.
The Neurizon team looks forward to seeing all those investors who can join us at the coming events, which are part
of a national investor engagement series. Additional dates and capital city locations will be announced shortly.
-ENDS-
Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com
Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222
This announcement has been authorised for release by the Interim Executive Chairman on behalf of the Board of
Neurizon Therapeutics Limited.
For further information and questions, please contact:
Neurizon Therapeutics
Lidija Damjanovic
Marketing & Corporate Affairs
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504
Australia Investor Relations
Henry Jordan
Six Degrees Investor Relations
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538
U.S. Investor Relations
Matthew Selinger
Integrous Communications
Email: mselinger@integcom.us
Phone: +1 415-572-8152
About Neurizon Therapeutics Limited
Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing
treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the
treatment of ALS, which is the most common form of motor neurone disease. Neurizon’s strategy is to accelerate
access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader
neurodegenerative applications. Through international collaborations and rigorous clinical programs, Neurizon is
dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an
investigational product and is not approved for commercial use in any jurisdiction.
Neurizon Investor Hub
We encourage you to utilise our Investor Hub for any enquiries regarding this
announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view
video summaries of key announcements.
To access Neurizon Investor Hub please scan the QR code or visit
https://investorhub.neurizon.com
Neurizon® is a registered trademark of Neurizon Therapeutics Limited
Share your feedback
Discover